Modality
Degrader
MOA
EGFRi
Target
BET
Pathway
Innate Imm
PAHHuntington's
Development Pipeline
Preclinical
~Apr 2012
→ ~Jul 2013
Phase 1
~Oct 2013
→ ~Jan 2015
Phase 2
~Apr 2015
→ ~Jul 2016
Phase 3
~Oct 2016
→ ~Jan 2018
NDA/BLA
Apr 2018
→ Dec 2027
NDA/BLACurrent
NCT04820807
1,212 pts·PAH
2018-04→2027-12·Active
1,212 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (1)
2027-12-031.7y awayPh3 Readout· PAH
Trial Timeline
Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q4
NDA/BLA
Active
Catalysts
Ph3 Readout
2027-12-03 · 1.7y away
PAH
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04820807 | NDA/BLA | PAH | Active | 1212 | CfB |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-5767 | Pfizer | Phase 1/2 | BET | |
| Niranesiran | Johnson & Johnson | Phase 2 | KIF18A | |
| JNJ-5094 | Johnson & Johnson | Phase 2/3 | GIP-R | |
| RHH-1969 | Roche | Approved | BET | |
| NVS-5439 | Novartis | Preclinical | BET | |
| Ivocapivasertib | Bristol-Myers Squibb | Phase 1 | BET | |
| GSK-2051 | GSK | Phase 1 | PSMA | |
| GIL-8529 | Gilead Sciences | Phase 1/2 | JAK1 | |
| Adagracapivasertib | BeiGene | NDA/BLA | BET | |
| 207-5197 | Samsung Biologics | Approved | BET |